Recent Finacing
Recent Raise
Resalis Therapeutics develops RES‑010, an antisense oligonucleotide targeting miR‑22 to reprogram metabolic pathways for obesity and NAFLD, demonstrating durable preclinical efficacy and preparing first-in-human trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Resalis Therapeutics.
